Cabaletta Bio, Inc. (CABA): Operating Cash Flow
-$131.08M
Year ended 2025-12-31
-$153.93M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$131.08M | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | -$88.22M | n/m | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | -$53.55M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$46.38M | n/m | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | -$34.11M | n/m | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | -$26.77M | n/m | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | -$16.05M | n/m | 2021-03-16, From 2019-01-01 |
| 2018-12-31 | -$4.66M | n/a | 2020-03-30, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | -$131.08M | n/m |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | -$84.74M | n/m |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | -$44.78M | n/m |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$177.23M | n/m |
| Compugen Ltd (CGEN) | 2025-12-31 | $31.63M | -36.2% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | -$110.99M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$65.84M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$47.84M | n/m |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | -$27.79M | n/m |
Compare CABA, AURA, SABS, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗